Status:
COMPLETED
Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis
Lead Sponsor:
Amgen
Collaborating Sponsors:
Immunex Corporation
Conditions:
Juvenile Rheumatoid Arthritis
Eligibility:
All Genders
2-18 years
Brief Summary
This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subje...
Eligibility Criteria
Inclusion
- JRA by American College of Rheumatology (ACR) criteria - Active joints - Initiate etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone, or methotrexate with other DMARDs within 6 months of entry into Registry
- Polyarticular or systemic RA in 3 or more joints at start of treatment
Exclusion
Key Trial Info
Start Date :
June 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00078793
Start Date
June 1 2000
End Date
January 1 2008
Last Update
May 14 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.